NCT01013142 - Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

MN-221 (Dose Group 1)

i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour

DRUG

MN-221 (Dose Group 2)

i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour

DRUG

MN-221 (Dose Group 3)

i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour

Trial Locations (7)

SNBL CLinical Pharmacology Center, Baltimore

Florida Pulmonary Research Institue, LLC, Winter Park

Vita Research Solutions & Medical Center, Inc., Tamarac

Vince and Associates Clinical Research, Overland Park

Gulf Coast Research, LLC, Lafayette

Dedicated Phase I, Phoenix

California Research Medical Group, INC, Fullerton